Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation

多囊肾病放射影像研究联盟 (CRISP) IV：终末期肾病的预后和生物标志物验证

• 批准号: 9906761
• 负责人: Alan S Yu
• 金额: $ 67.54万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2022-03-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9906761
• 关键词: Alabama; Ancillary Study; Autosomal Dominant Polycystic Kidney; Biochemical; Biochemical Genetics; Biochemical Markers; Biological Markers; Biological Specimen Banks; Blood; Cessation of life; Chicago; Clinic; Clinical Trials; Cohort Studies; Communities; Creatinine; Data; Data Set; Development; Disease; Disease Progression; Disease model; End stage renal failure; Enrollment; Evaluation; Genes; Genetic Markers; Goals; Growth; Health; Image; Image Analysis; Individual; Intervention Trial; Kansas; Kidney; Life; Life Expectancy; Logistic Regressions; Longitudinal observational study; Measurement; Medical center; Modeling; Outcome; Participant; Patient Care; Patients; Phenotype; Polycystic Kidney Diseases; Predictive Value; Prognostic Marker; Prospective cohort study; Quality of life; Renal Blood Flow; Renal function; Research Personnel; Resources; Role; Sampling; Serum; Shapes; Site; Techniques; Testing; Therapy trial; Time; United States; Universities; Urine; Validation; Visit; artificial neural network; base; biomarker discovery; biomarker validation; blood flow measurement; classification trees; clinical care; cohort; design; disease natural history; exosome; follow-up; genetic variant; imaging genetics; imaging study; improved; individual patient; innovation; model building; novel; novel marker; novel strategies; novel therapeutics; outcome forecast; predictive modeling; predictive tools; preservation; prognostic; prognostic tool; prognostic value; prospective; proteomic signature; radiological imaging; urinary; young adult

Project Summary The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is a unique, longitudinal, observational cohort study of 241 autosomal dominant polycystic kidney disease (ADPKD) patients that began in 2000. The consortium consists of researchers at University of Alabama, University of Chicago, Emory University, University of Kansas Medical Center, Mayo Clinic, and University of Pittsburgh. The broad, long- term objectives of CRISP are to define the natural history of the disease and to discover prognostic biomarkers in early disease that can accurately predict long-term renal outcomes. The goals of CRISP IV are to continue follow-up of the CRISP cohort for 5 more years so as to refine models of CKD progression and strengthen the association between htTKV and renal outcomes, to validate disease models using existing and additional follow-up data from the HALT PKD study, and to incorporate powerful emerging imaging, genetic and biochemical biomarkers to improve the accuracy of prognostication for individual patients. To achieve this, the specific aims are: Aim 1. Continue follow-up of CRISP and HALT participants. All CRISP participants that have not reached ESRD, together with HALT Study A participants followed at CRISP sites, will be followed up with annual serum creatinine measurements. Aim 2. Develop improved models to predict GFR trajectories and progression to ESRD. Existing logistic regression and trajectory models will be refined and new approaches such as artificial neural network and classification tree models developed, using CRISP data for model fitting and HALT-A data for external validation. Aim 3. Develop novel imaging, biochemical and genetic biomarkers of disease progression. Highly promising new biomarkers that are emerging from ancillary studies or being developed in parallel ongoing studies at the CRISP centers, will be evaluated for their ability to improve the accuracy of prognostic models.

项目概要 多囊肾病放射影像研究联盟 (CRISP) 是一个独特的、纵向的、 241 名常染色体显性多囊肾病 (ADPKD) 患者的观察性队列研究已开始 2000年。该联盟由阿拉巴马大学、芝加哥大学、埃默里大学的研究人员组成 大学、堪萨斯大学医学中心、梅奥诊所和匹兹堡大学。又宽又长—— CRISP 的长期目标是定义疾病的自然史并发现预后生物标志物 在早期疾病中可以准确预测长期肾脏结果。 CRISP IV 的目标是继续 对 CRISP 队列进行 5 年以上的随访，以完善 CKD 进展模型并加强 htTKV 和肾脏结果之间的关联，使用现有的和额外的疾病模型来验证 来自 HALT PKD 研究的后续数据，并结合强大的新兴成像、遗传和 生化生物标志物可提高个体患者预后的准确性。为了实现这一目标， 具体目标是： 目标 1. 继续跟踪 CRISP 和 HALT 参与者。所有 CRISP 参与者 未达到 ESRD 的患者将与在 CRISP 站点跟踪的 HALT 研究 A 参与者一起进行随访 每年进行血清肌酐测量。目标 2. 开发改进的模型来预测 GFR 轨迹和 进展至 ESRD。现有的逻辑回归和轨迹模型将得到改进，并采用新方法 比如开发的人工神经网络和分类树模型，利用CRISP数据进行模型拟合 和用于外部验证的 HALT-A 数据。目标 3. 开发新的成像、生化和遗传生物标志物 疾病进展。辅助研究中出现或正在开发的极具前景的新生物标志物 CRISP 中心并行正在进行的研究中开发的，将评估其改善 预测模型的准确性。